HOWL Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
21.0M
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
21.0M
0
0
0
0
Operating Expenses
13.8M
+4.3%
13.3M
+40.9%
9.4M
-40.1%
15.7M
-10.4%
17.5M
R&D
6.2M
-24.7%
8.2M
+18.0%
6.9M
-40.4%
11.6M
-11.5%
13.1M
SG&A
7.7M
+50.9%
5.1M
+104.8%
2.5M
-39.3%
4.1M
-7.0%
4.4M
Operating Income
7.2M
+153.9%
-13271000
-40.9%
-9418000
+40.1%
-15726000
+10.4%
-17542000
EBITDA
9.6M
+174.7%
-12873000
-42.7%
-9018000
+41.2%
-15324000
+10.6%
-17136000
Net Income
3.7M
+127.1%
-13532000
-61.5%
-8381000
+48.8%
-16370000
+9.0%
-17982000
EPS (Basic)
$0.08
+128.6%
$-0.28
-64.7%
$-0.17
+52.8%
$-0.36
+10.0%
$-0.40
EPS (Diluted)
$0.08
+128.6%
$-0.28
-75.0%
$-0.16
+55.6%
$-0.36
+10.0%
$-0.40
Shares (Diluted)
48.6M
-1.6%
49.4M
-4.3%
51.6M
+12.7%
45.8M
+1.8%
45.0M
Werewolf Therapeutics (HOWL) โ€” Financials